Literature DB >> 2222130

Long-term therapeutic use of benzodiazepines. II. Effects of gradual taper.

E Schweizer1, K Rickels, W G Case, D J Greenblatt.   

Abstract

We compared the effect on withdrawal severity and acute outcome of a 25% per week taper of short half-life vs long half-life benzodiazepines in 63 benzodiazepine-dependent patients. Patients unable to tolerate taper were permitted to slow the taper rate. Ninety percent of patients experienced a withdrawal reaction, but it was rarely more than mild to moderate. Nonetheless, 32% of long half-life and 42% of short half-life benzodiazepine-treated patients were unable to achieve a drug-free state. The most difficulty was experienced in the last half of taper. Baseline personality, high Eysenck neuroticism, female sex, and mild-to-moderate alcohol use were found to be more significant predictors of withdrawal severity than the daily benzodiazepine dose or benzodiazepine half-life. These findings suggest that personality factors contribute significantly to the patient's difficulties with gradual benzodiazepine discontinuation of therapeutic doses of benzodiazepines.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2222130     DOI: 10.1001/archpsyc.1990.01810220024003

Source DB:  PubMed          Journal:  Arch Gen Psychiatry        ISSN: 0003-990X


  21 in total

Review 1.  Is there still a role for benzodiazepines in general practice?

Authors:  M B King
Journal:  Br J Gen Pract       Date:  1992-05       Impact factor: 5.386

2.  Benzodiazepines and tinnitus.

Authors:  L Beeley
Journal:  BMJ       Date:  1991-06-15

Review 3.  Deprescribing Benzodiazepines in Older Patients: Impact of Interventions Targeting Physicians, Pharmacists, and Patients.

Authors:  Brendan J Ng; David G Le Couteur; Sarah N Hilmer
Journal:  Drugs Aging       Date:  2018-06       Impact factor: 3.923

4.  Tapering off benzodiazepines in long-term users: an economic evaluation.

Authors:  Richard C Oude Voshaar; Paul F M Krabbe; Wim J M J Gorgels; Eddy M M Adang; Anton J L M van Balkom; Eloy H van de Lisdonk; Frans G Zitman
Journal:  Pharmacoeconomics       Date:  2006       Impact factor: 4.981

5. 

Authors:  Kevin Pottie; Wade Thompson; Simon Davies; Jean Grenier; Cheryl A Sadowski; Vivian Welch; Anne Holbrook; Cynthia Boyd; Robert Swenson; Andy Ma; Barbara Farrell
Journal:  Can Fam Physician       Date:  2018-05       Impact factor: 3.275

6.  Long-term use of benzodiazepines in participants with comorbid anxiety and alcohol use disorders.

Authors:  Timothy I Mueller; Maria E Pagano; Benjamin F Rodriguez; Steven E Bruce; Robert L Stout; Martin B Keller
Journal:  Alcohol Clin Exp Res       Date:  2005-08       Impact factor: 3.455

Review 7.  Current benzodiazepine issues.

Authors:  J H Woods; G Winger
Journal:  Psychopharmacology (Berl)       Date:  1995-03       Impact factor: 4.530

8.  The dependence potential of short half-life benzodiazepines: a meta-analysis.

Authors:  D D Hallfors; L Saxe
Journal:  Am J Public Health       Date:  1993-09       Impact factor: 9.308

Review 9.  Switching from neurostimulant therapy to atomoxetine in children and adolescents with attention-deficit hyperactivity disorder : clinical approaches and review of current available evidence.

Authors:  Suyash Prasad; Chris Steer
Journal:  Paediatr Drugs       Date:  2008       Impact factor: 3.022

10.  Deprescribing benzodiazepine receptor agonists: Evidence-based clinical practice guideline.

Authors:  Kevin Pottie; Wade Thompson; Simon Davies; Jean Grenier; Cheryl A Sadowski; Vivian Welch; Anne Holbrook; Cynthia Boyd; Robert Swenson; Andy Ma; Barbara Farrell
Journal:  Can Fam Physician       Date:  2018-05       Impact factor: 3.275

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.